Alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients

Journal of Pharmacy Practice

Volumn 23, Issue 1, 2010, Pages 6-18

  Winterboer, Tammy M ^a,b   Lecci, Kassandra A ^a   Olsen, Keith M ^a,b  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Antibiotics; Critical care; Intensive care; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DAPTOMYCIN; DORIPENEM; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LIPOPEPTIDE; MEROPENEM; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HOSPITAL INFECTION; HUMAN; INFECTION; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA; ANIMAL; CRITICAL ILLNESS; DOSE RESPONSE; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; PHYSIOLOGY; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS;

EID: 77949357975     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190009356550     Document Type: Article

References (96)

1. Angus DC, Linde-Zwirble WT, Lidicker A, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29(7):1303-1310.
2. Dombrovskiy VY, Martin AA, Sunderram J, et al. Facing the challenge: decreasing case fatality rates in severe sepsis despite increasing hospitalizations. Crit Care Med. 2005;33(11):2555-2562.
3. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-1596.
4. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653-665.
5. Bliziotis IA, Samonis G, Vardakas KZ, et al. Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance: a metaanalysis of randomized, controlled trials. Clin Infect Dis. 2005;41(2):149-158.
6. MacArthur RD, Miller M, Albertson T, et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis. 2004;38(2): 284-288.
7. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45(8):755-773.
8. Aarts MA, Hancock JN, Heyland D, et al. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2008;36(1):108-117.
9. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.
10. Bellomo R, Roncom C, Kellum JA, et al, and ADQI workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):204-212.
11. Joy M, Matzke G, Armstrong D, et al. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother. 1998;32(3):362-375.
12. Marshall MR, Golper TA, Shaver MJ, et al. Sustained lowefficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int. 2001;60(2):777-785.
13. Salahudeen AK, Kumar V, Madan N, et al. Sustained low efficiency dialysis in the continuous mode (C-SLED): dialysis efficacy, clinical outcomes, and survival predictors in critically ill cancer patients. Clin J Am Soc Nephrol. 2009;4(8):1338-1346.
14. Ambrose PG, Bhavanani SM, Rubino CM, et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007;44(1):79-86.
15. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and me. Clin Infect Dis. 1998;26(1):1-12.
16. Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimcrob Agents Chemother. 2006;50(4):1372-1375.
17. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother. 1996;38(5): 865-869.
18. Ackerman BH, Taylor EH, Olsen KM, et al. Vancomycin serum protein binding determination by ultrafiltration. Drug Intell Clin Pharm. 1988;22(4):300-303.
19. Moutan JW, Theuretzbacher U, Craig WA, et al. Tissue concentrations: do we ever learn? J Antimicrob Chemother. 2008;61(2): 235-237.
20. Craig WW, Eberts SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl. 1991;74:63-70.
21. Olsen KM, Rudis MI, Rebuck JA, et al. Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med. 2004;32(8):1678-1682.
22. Murry KR, McKinnon PS, Mitrzyk B, et al. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy. 1999;19(11):1252-1260.
23. Barclay ML, Kirkpatrick C, Begg EJ. Once daily aminoglycoside therapy: is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet. 1999;36(2):89-98.
24. Lacy MK, Nicolau DP, Nightingale CH, et al. The pharmacodynamics of aminoglycosides. Clin Infect Dis. 1998;27(1):23-27.
25. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin N Am. 2003;17(3):503-528.
26. Frimodt-Moller N. How predictive is PK/PD for antibacterial agents? Int J Antimicrob Agents. 2002;19(4):333-339.
27. Drusano GL, Johnson DE, Rosen M, et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993; 37(3):483-490.
28. Rea RS, Capitano B, Bies R, et al. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit. 2008;30(6):674-681.
29. Beavers KD, Wilson CG, Kiser TH, et al. Pharmacodynamic evaluation of the Hartford Nomogram for dosing of aminoglycosides in intensive care unit patients using Monte Carlo simulation. ACCP 2007 Meeting Abstract #367.
30. Owens RC, Bhavnani SM, Ambrose PG. Assessment of pharmacokinetic - pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2005;51(1):45-49.
31. Nicolau DP, Ambrose PG. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of. Streptococcus pneumonia. Am J Med. 2001;111(9A):13S-18S.
32. MacGowan AP, Wootton M, Holt HA. The antibacterial efficacy of levofloxacin and ciprofloxacin against P aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. J Antimicrob Chemother. 1999;43(3):345-349.
33. Olsen KM, Gentry-Nielsen MJ, Preheim LC. Effect of ethanol on the efficacy of levofloxacin, moxifloxacin and trovafloxacin in a pneumococcal pneumonia model. Antimicrob Agents Chemother. 2006;50(1):210-219.
34. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP. 1991;25(10):1050-1057.
35. Highet VS, Forrest A, Ballow CH, et al. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predicative of efficacy. J Antimicrob Chem. 1999;43(suppl A):55-63.
36. Drusano GL, Ambrose PG, Bhavnani SM, et al. Back to the future:using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007;45(6):753-760.
37. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet. 1995;28(2):143-160.
38. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003;112(2): 275-285.
39. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998;42(3):521-527.
40. Schentag JJ, Gilliland K, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis. 2001;32(suppl 1):S39-S46.
41. Olsen KM, Winterboer TM, Hermsen E, et al. Do we achieve pharmacodynamic targets with gentamicin and tobramycin in critically ill patients? Crit Care Med. 2008;35(12):A172.
42. Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis. 2007; 44(12):1543-1548.
43. Lamer C, deBeco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother. 1993;37(2): 281-286.
44. Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med. 2005;33(9):1983-1987.
45. Shorr AF, Combes A, Kollef MG, et al. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med. 2006;34(3):700-706.
46. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(14):388-416.
47. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Disease Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009;66(1): 82-98.
48. Moise PA, Forrest A, Bhavnani SM, et al. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm. 2000;57(suppl 2):S4-S9.
49. Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43(13):925-942.
50. CDC. Reduced susceptibility of Staphylococcus aureus to vancomycin. MMWR. 1997;46(27):624-626.
51. Tenover FC, Moellering RC. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44(9):1208-1215.
52. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Int Med. 2006;166(19):2138-2144.
53. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52(9):3315-3320.
54. Sakoulas G, Moise-Broder PA, Schentag JJ, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42(6):2398-2402.
55. Steinkraus G, White R, Friedwich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-2005. J Antimicrob Chemother. 2007;60(4):788-794.
56. Wang G, Hindler JF, Ward KW, et al. Increased vancomycin MIC for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44(11): 3883-3886.
57. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44(12):1526-1542.
58. Del Mar Fernandez de Gatta Garcia M, Revilla N, Calvo MV, et al. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Inten Care Med. 2006;33(2):279-285.
59. Charles PGP, Ward PB, Johnson PDR, et al. Clinical features associated with bacteremia due to heterogeneous vancomycinintermediate Staphylococcus aureus. Clin Infect Dis. 2004; 38(3):448-451.
60. Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330-1335.
61. Rybak MJ, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin, alone and in combination with an aminoglycoside. J Antimicrob Chemother. 1990;25(4):679-687.
62. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2001;45(9):2460-2467.
63. Hutschala D, Kinster C, Skhirdladze MD, et al. Influence of vancomycin on renal function in critically ill patients after cardiac surgery. Anesthesiology. 2009;111(2):356-365.
64. Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of β-lactam antibiotics. Crit Care Med. 2009;37(6):2071-2078.
65. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodyanmic concepts into clinical practice: focus on β-lactam antibiotics. Pharmacotherapy. 2006;26(9):1320-1332.
66. Roberts JA, Kirkpatrick CM, Roberts MS, et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64(1):142-150.
67. Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care. 2007;13(5):598-606.
68. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous infusion and intermittent ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38(5):931-936.
69. Alou L, Aguilar L, Sevillano D, et al. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J Antimicrob Chemother. 2005;55(2):209-213.
70. Psathas PA, Kuzmission A, Ikeda K, et al. Stability of doripenem in vitro in representative infusion solutions and infusion bags. Clin Therap. 2008;30(11):2075-2087.
71. Kuti Jl, Nightingale CH, Knault RF, et al. Pharmacokinetic properties of and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther. 2004;26(4):493-501.
72. Trissel LA. Handbook of Injectable Drugs. 15th ed. Bethesda: American Society of Health-System Pharmacists; 2008.
73. Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother. 2005;49(1): 461-463.
74. Sakka SG, Glauner AK, Bulitta JB, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, control trial. Antimicrob Agents Chemother. 2007;51(9): 3304-3310.
75. Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008;36(4):1089-1096.
76. Nicolau DP. Pharmacodynamic optimization of β-lactam antibiotics in the patient care setting. Crit Care. 2008;12(suppl 4):1-5.
77. Kim A, Sutherland CA, Kuti JL, et al. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion. Pharmacotherapy. 2007;27(11):1490-1497.
78. Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended infusion dosing strategy. Clin Infect Dis. 2007; 44(3):357-363.
79. Scaglione F, Mouton JW, Mattina R, et al. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob Agents Chemother. 2003;47(9):2749-2755.
80. Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am. 2003;17(3): 529-543.
81. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37(5):1073-1081.
82. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 2001;7(11):589-596.
83. Zelenitsky SA, Harding GK, Sun S, et al. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother. 2003;52(4):668-674.
84. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279(2):125-129.
85. Wispelwey B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Infect Dis. 2005; 41(suppl 2):S127-S135.
86. Drusano GL, Preston SL, Fowler C, et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis. 2004;189(9):1590-1597.
87. Lister PD, Sanders CC. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1999;43(5):1118-1123.
88. Zelenitsky SA, Ariano RE, Lacovides H, et al. AUC/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. J Antimicrob Chemother. 2003;51(4):905-911.
89. Jones RN, Rubino CM, Bhavnani SM, et al. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother. 2003;47(1):292-296.
90. Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis. 2005;40(suppl 2):S99-S104.
91. Burgess DS, Hall RG. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. Clin Therap. 2007;29(7):1421-1427.
92. Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J Med. 2006;119(6A):S37-S44.
93. Olofsson SK, Macusson LL, Stromback A, et al. Dose-related selection of fluoroquinolone-resistance Escherichia coli. J Antimicrob Chemother. 2007;60(4):795-801.
94. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840-851.
95. Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother. 2009;53(5):1863-1867.
96. Jones RN, Rubino CM, Bhavnani SM, et al. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother. 2003;47(1):292-296.